Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by pelabooston Dec 16, 2023 6:51am
158 Views
Post# 35788019

RE:RE:RE:RE:RE:RE:RE:RE:Fair Market Value

RE:RE:RE:RE:RE:RE:RE:RE:Fair Market ValueGood Morning inthno. It was my fault. I was almost certain AN did not have Japan (thank goodness) and should have confirmed that myself, but was looking at MM at the time. Neither should I have asked the question about CAR T and liquid and solid tumors. A very difficult question to answer, especially on this medium. I do wonder if pela and CAR T fit with MM.

For what it's worth I believe you to be a frustrated long, and that you have the best and most accessible ONC archive. I would be very surprised if MC exercised those options. Frankly I did not expect it; he has shown his colours on many occasions. On the plus side. he seems to have steered ONC to some good results, and is still able to attract bright people.

However, raising funds from Anson raises flags. I do not get it. I certainly do not think the braintrust  at ONC did us any favours. The smart money here has traded the stock over the years; I would have also, but I am no good at it.

Anyway ONC (owing to little cash) seems to be involved in too many projects. I may be wrong; perhaps it is a necessary strategy. Shareholders should remember a lot of the research funding is coming from other than our own coffers.

I do think the runway is very short, and will be disappointed if we do not have material change very soon. Read that as substantial funding or a buyout. I am going to hold.

Have a great holiday.

<< Previous
Bullboard Posts
Next >>